For research use only. Not for therapeutic Use.
Taletrectinib(Cat No.:I014971), also known as DS-6051b, is a potent and orally active inhibitor designed to target ROS1 and NTRK (Neurotrophic Receptor Tyrosine Kinase) oncogenic fusion proteins. These fusion proteins are prevalent in various cancers and contribute to tumor growth and progression. By selectively inhibiting ROS1 and NTRK, taletrectinib disrupts aberrant signaling pathways, potentially halting cancer cell proliferation and promoting apoptosis. This compound offers a targeted therapeutic approach for ROS1- and NTRK-driven cancers, showing promise as a new-generation treatment option.
| Catalog Number | I014971 |
| CAS Number | 1505515-69-4 |
| Molecular Formula | C₂₉H₃₄FN₅O₅ |
| Purity | ≥95% |
| Target | ROS Kinase |
| IUPAC Name | 3-[4-[(2R)-2-aminopropoxy]phenyl]-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine;hexanedioic acid |
| InChI | InChI=1S/C23H24FN5O.C6H10O4/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18;7-5(8)3-1-2-4-6(9)10/h3-13,15-16H,14,25H2,1-2H3,(H,27,28);1-4H2,(H,7,8)(H,9,10)/t15-,16-;/m1./s1 |
| InChIKey | DORJQZDOULKINH-QNBGGDODSA-N |
| SMILES | C[C@H](COC1=CC=C(C=C1)C2=CN=C3N2N=C(C=C3)N[C@H](C)C4=CC(=CC=C4)F)N.C(CCC(=O)O)CC(=O)O |
| Reference | [1]. Katayama R, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604. Published 2019 Aug 9.<br>[2]. Fujiwara Y, et al. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018;9(34):23729-23737. Published 2018 May 4. |
